KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non Operating Income (2018 - 2025)

Acadia Pharmaceuticals has reported Non Operating Income over the past 8 years, most recently at $596000.0 for Q4 2025.

  • Quarterly results put Non Operating Income at $596000.0 for Q4 2025, up 103.98% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (up 117.29% YoY), and the annual figure for FY2025 was $2.4 million, up 117.29%.
  • Non Operating Income for Q4 2025 was $596000.0 at Acadia Pharmaceuticals, up from $593000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for ACAD hit a ceiling of $4.8 million in Q1 2023 and a floor of -$15.0 million in Q4 2024.
  • Median Non Operating Income over the past 5 years was $384500.0 (2021), compared with a mean of -$817600.0.
  • Biggest five-year swings in Non Operating Income: crashed 379.21% in 2022 and later surged 1325.0% in 2023.
  • Acadia Pharmaceuticals' Non Operating Income stood at $1.6 million in 2021, then crashed by 344.61% to -$4.0 million in 2022, then tumbled by 156.55% to -$10.2 million in 2023, then plummeted by 46.91% to -$15.0 million in 2024, then skyrocketed by 103.98% to $596000.0 in 2025.
  • The last three reported values for Non Operating Income were $596000.0 (Q4 2025), $593000.0 (Q3 2025), and $594000.0 (Q2 2025) per Business Quant data.